APA

Kiladjian J., Massé A., Cassinat B., Mokrani H., Teyssandier I., le Couédic J., Cambier N., Almire C., Pronier E., Casadevall N., Vainchenker W., Chomienne C. & Delhommeau F. (20100914). Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. : Leukemia.

Chicago

Kiladjian J-J, Massé A, Cassinat B, Mokrani H, Teyssandier I, le Couédic J-P, Cambier N, Almire C, Pronier E, Casadevall N, Vainchenker W, Chomienne C and Delhommeau F. 20100914. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. : Leukemia.

Harvard

Kiladjian J., Massé A., Cassinat B., Mokrani H., Teyssandier I., le Couédic J., Cambier N., Almire C., Pronier E., Casadevall N., Vainchenker W., Chomienne C. and Delhommeau F. (20100914). Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. : Leukemia.

MLA

Kiladjian J-J, Massé A, Cassinat B, Mokrani H, Teyssandier I, le Couédic J-P, Cambier N, Almire C, Pronier E, Casadevall N, Vainchenker W, Chomienne C and Delhommeau F. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. : Leukemia. 20100914.